RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Beijing

北京 乳腺癌

All diseases in Beijing

20 hospitals in Beijing

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Beijing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 333 papers led
  2. 116 papers led
  3. 106 papers led
  4. 91 papers led
  5. 44 papers led
  6. 44 papers led
  7. 40 papers led
  8. 28 papers led
    No open trial led
  9. 28 papers led
  10. 25 papers led
    No open trial led
  11. 21 papers led
    No open trial led
  12. 21 papers led
    No open trial led
  13. 20 papers led
    No open trial led
  14. 14 papers led
    No open trial led
  15. 12 papers led
  16. 12 papers led
    No open trial led
  17. 4 papers led
    No open trial led
  18. 1 paper led
    No open trial led
  19. 0 papers led
  20. 0 papers led
    No open trial led

Breast cancer in every city Beijing on the disease page, with the national map

165

open trials on breast cancer with a hospital in Beijing

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Beijing as lead sponsor or study site. 95 of them are led by a hospital in Beijing. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT06993506

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou

  2. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  3. Recruiting
    Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07084519

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  4. Recruiting
    The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07203729

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  5. Recruiting
    A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07208149

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Changsha, Wuhan

  6. Recruiting
    A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07238894

    Age 18 years to 80 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  7. Recruiting
    A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07294508

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  8. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  9. Recruiting
    A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07354022

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  10. Recruiting
    CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07366112

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  11. Recruiting
    Response-Based Local Therapy for Regionally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07376538

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  12. Recruiting
    RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07413939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan

  13. Recruiting
    Ablation Compare With Surgery for Early Breast Cancer
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07484087

    Age 50 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  14. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  15. Recruiting
    A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07497386

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  16. Recruiting
    Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07498478

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan

  17. Recruiting
    Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07500428

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  18. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  19. Recruiting
    Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
    Phase
    Phase 4
    Started
    2026-07
    Posted
    Registry
    NCT07600164

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  20. Recruiting
    A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07648914

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  21. Recruiting
    A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07678957

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  22. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  23. Recruiting
    GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07738341

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  24. Recruiting
    A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT07753226

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  25. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  26. Recruiting
    Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07773818

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  27. Recruiting
    Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07848243

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  28. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  29. Recruiting
    Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT05321316

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  30. Recruiting
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06757634

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou

  31. Recruiting
    AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06767527

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  32. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06790693

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang

  33. Recruiting
    A Phase IIa Study to Evaluate NBQ72S
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06810804

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  34. Recruiting
    A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06839547

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  35. Recruiting
    Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06839560

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  36. Recruiting
    Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06908668

    Age 18 years to 70 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  37. Recruiting
    Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06909604

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  38. Recruiting
    A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
    Phase
    Phase 2/Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06926868

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  39. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  40. Recruiting
    ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT06970912

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  41. Recruiting
    Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT06991790

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  42. Recruiting
    GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT06994507

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  43. Recruiting
    Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07008976

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou

  44. Recruiting
    A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07010939

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  45. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  46. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  47. Recruiting
    Trop-2 Targeted PET Probes in Advanced TNBC
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT07046455

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  48. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  49. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  50. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  51. Recruiting
    A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07071337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  52. Recruiting
    Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07095023

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Shantou, Shenzhen, Wenzhou

  53. Recruiting
    A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07111832

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  54. Recruiting
    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07114601

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  55. Recruiting
    Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07117864

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  56. Recruiting
    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07174336

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan

  57. Recruiting
    An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07222267

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen

  58. Recruiting
    68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07331532

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  59. Recruiting
    A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07532434

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University Third HospitalBeijing

  60. Recruiting
    Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07586826

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  61. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  62. Recruiting
    Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
    Phase
    N/A
    Started
    2024-01
    Posted
    Registry
    NCT06197581

    Age 18 years to 70 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  63. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  64. Recruiting
    A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06383767

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  65. Recruiting
    Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
    Phase
    Early phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06411678

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  66. Recruiting
    Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06418594

    Age 18 years to Not stated; women only (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  67. Recruiting
    Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06433609

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  68. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  69. Recruiting
    A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06531486

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  70. Recruiting
    Hypofractionated Online Adaptive Radiotherapy of Breast Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06568705

    Age 35 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  71. Recruiting
    Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06596915

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  72. Recruiting
    A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06609187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  73. Recruiting
    Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06649565

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  74. Recruiting
    Large Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06660628

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  75. Recruiting
    Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06715020

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  76. Recruiting
    Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06725082

    Age 18 years to 80 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  77. Recruiting
    Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06757621

    Age 45 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  78. Recruiting
    Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06771609

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  79. Recruiting
    A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT06776861

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  80. Recruiting
    The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
    Phase
    Phase 2/Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06958627

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  81. Recruiting
    Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT07251868

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  82. Recruiting
    Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
    Phase
    N/A
    Started
    2023-05
    Posted
    Registry
    NCT05494502

    Age 18 years to 85 years (registered criteria)

    Led by Peking University First Hospital; 1 listed hospital as study siteBeijing

  83. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  84. Recruiting
    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-04
    Posted
    Registry
    NCT05744687

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan

  85. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  86. Recruiting
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05872347

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou

  87. Recruiting
    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05891093

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  88. Recruiting
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05894239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan

  89. Recruiting
    Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05909332

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  90. Recruiting
    Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT05950945

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou

  91. Recruiting
    Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05983107

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  92. Recruiting
    Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT06035016

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  93. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  94. Recruiting
    Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT06081959

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  95. Recruiting
    99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06104085

    Age 18 years to 80 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  96. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  97. Recruiting
    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06120283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang

  98. Recruiting
    Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06167694

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  99. Recruiting
    Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT06908291

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  100. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  101. Recruiting
    Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05341141

    Age 20 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  102. Recruiting
    Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
    Phase
    N/A
    Started
    2022-03
    Posted
    Registry
    NCT05345860

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  103. Recruiting
    JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05490472

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan

  104. Recruiting
    68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
    Phase
    Early phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05549024

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  105. Recruiting
    Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study
    Phase
    Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05576389

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  106. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  107. Recruiting
    A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05603078

    Age Not stated to 55 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  108. Recruiting
    Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
    Phase
    Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05762900

    Age 35 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  109. Recruiting
    Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2022-04
    Posted
    Registry
    NCT05804916

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  110. Recruiting
    Comparison Between Prepectoral and Subpectoral Breast Reconstruction
    Phase
    Not given
    Started
    2022-03
    Posted
    Registry
    NCT05833659

    Age 18 years to 70 years; women only (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  111. Recruiting
    A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT06313983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  112. Recruiting
    Super-Hypofractionated Partial Breast Irradiation
    Phase
    N/A
    Started
    2022-04
    Posted
    Registry
    NCT06615466

    Age 45 years to 74 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  113. Recruiting
    A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2022-09
    Posted
    Registry
    NCT06954961

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  114. Recruiting
    Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
    Phase
    Phase 3
    Started
    2022-06
    Posted
    Registry
    NCT06998108

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  115. Recruiting
    Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2021-03
    Posted
    Registry
    NCT04750122

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  116. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  117. Recruiting
    Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04836156

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  118. Recruiting
    Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
    Phase
    Phase 2
    Started
    2020-07
    Posted
    Registry
    NCT04481932

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  119. Recruiting
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04557449

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou

  120. Recruiting
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2020-11
    Posted
    Registry
    NCT04606446

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an

  121. Recruiting
    Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT
    Phase
    N/A
    Started
    2020-07
    Posted
    Registry
    NCT05314114

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  122. Recruiting
    De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06692725

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  123. Recruiting
    Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06693024

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  124. Recruiting
    Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06693037

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  125. Recruiting
    Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06700382

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  126. Recruiting
    Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06711068

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  127. Recruiting
    Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06722599

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  128. Recruiting
    Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06722612

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  129. Recruiting
    Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2015-07
    Posted
    Registry
    NCT02535221

    Age 35 years to 55 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  130. Recruiting
    De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
    Phase
    Not given
    Started
    2015-01
    Posted
    Registry
    NCT06700369

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  131. Recruiting
    Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
    Phase
    Not given
    Started
    2015-01
    Posted
    Registry
    NCT06711055

    Age not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  132. Not yet recruiting
    ADC Based Therapy Accroding to HER2 Heterogeneous
    Phase
    Phase 2
    Started
    2027-01
    Posted
    Registry
    NCT07844018

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  133. Not yet recruiting
    A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07294339

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  134. Not yet recruiting
    Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07317778

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  135. Not yet recruiting
    Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07367542

    Age 18 years to Not stated; women only (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  136. Not yet recruiting
    Efficacy and Safety of Qibei Jiedu Formula for Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07380230

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  137. Not yet recruiting
    Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Breast Cancer Surgery Patients
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07458646

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  138. Not yet recruiting
    Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07481903

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesBeijing, Nanjing, Tianjin

  139. Not yet recruiting
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07560124

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Harbin

  140. Not yet recruiting
    5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07589101

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  141. Not yet recruiting
    Clinical Application of Vagus Nerve Stimulation Combined With Immunoregulatory T Cells in Alleviating Aromatase Inhibitor-Induced Pain
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07593365

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  142. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  143. Not yet recruiting
    Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07657442

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  144. Not yet recruiting
    A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07672743

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  145. Not yet recruiting
    Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07684456

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  146. Not yet recruiting
    A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07782086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou

  147. Not yet recruiting
    SLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary Nodes
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07791771

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  148. Not yet recruiting
    Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT06556862

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  149. Not yet recruiting
    Familial Breast Cancer in China
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06833216

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  150. Not yet recruiting
    Acupuncture for Anxiety and Depression
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT06994351

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guang'anmen HospitalBeijing

  151. Not yet recruiting
    Acupuncture for Anxiety/Depression in Patients With Breast Cancer
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07183813

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guang'anmen HospitalBeijing

  152. Not yet recruiting
    Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
    Phase
    Phase 4
    Started
    2024-01
    Posted
    Registry
    NCT06245824

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  153. Not yet recruiting
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06614751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  154. Not yet recruiting
    Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05983094

    Age 18 years to 70 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  155. Not yet recruiting
    The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
    Phase
    Phase 2
    Started
    2022-06
    Posted
    Registry
    NCT05431504

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  156. Not yet recruiting
    Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
    Phase
    Phase 3
    Started
    2021-02
    Posted
    Registry
    NCT04736589

    Age 18 years to 85 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  157. Not yet recruiting
    A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients
    Phase
    Not given
    Started
    2020-06
    Posted
    Registry
    NCT04426136

    Age 70 years to Not stated; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  158. Enrolling by invitation
    Exercise Intervention for Breast Cancer Patients With Sarcopenia
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07732101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  159. Enrolling by invitation
    Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06650748

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  160. Enrolling by invitation
    A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06791161

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  161. Enrolling by invitation
    A Study Comparing the Differences Between Young and Non-young Breast Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06793306

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  162. Enrolling by invitation
    Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)
    Phase
    Phase 2/Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06910072

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  163. Enrolling by invitation
    Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06405269

    Age 18 years to 40 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  164. Enrolling by invitation
    Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06405295

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  165. Enrolling by invitation
    Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT07359404

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Beijing

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Beijing, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Aerospace Center Hospital航天中心医院nonenonenonenonenonenonenonenonenonenonenone111nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone332none0nonenonenonenonenonenone1nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Air Force General Hospital中国人民解放军空军特色医学中心nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing An Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Anding Hospital首都医科大学附属北京安定医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Anzhen Hospital首都医科大学附属北京安贞医院none6nonenonenonenonenonenonenonenonenone10nonenonenonenonenone2none0nonenonenonenonenone0nonenonenonenone19611 open805 opennonenone30none1nonenonenone0nonenone213nonenonenone1nonenonenonenonenonenonenonenonenonenone
Beijing Army General Hospital中国人民解放军总医院第七医学中心nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Boren Hospital北京高博博仁医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone01nonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Chao-Yang Hospital首都医科大学附属北京朝阳医院none81812662 open1821nonenonenone2601252nonenonenone20none00nonenonenonenonenonenonenone342 open340none3none13none1nonenonenonenone1none4nonenonenone321nonenonenone0nonenonenonenone
Beijing Chest Hospital首都医科大学附属北京胸科医院nonenonenonenone802 opennonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Children's Hospital首都医科大学附属北京儿童医院nonenonenonenonenonenonenonenone46none5none331 open4none49311 open251332012nonenone2none156241743nonenonenone100none11170nonenonenonenonenone131nonenonenone0nonenone
Beijing Daxing District People's Hospital北京市大兴区人民医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Ditan Hospital, Capital Medical University首都医科大学附属北京地坛医院nonenone72nonenonenonenone50nonenonenonenonenonenonenonenonenonenone7nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone1nonenonenonenonenonenonenonenonenonenonenonenone110nonenonenonenonenonenonenonenonenone
Beijing Friendship Hospital首都医科大学附属北京友谊医院none12511 open457 open3810401 opennone11none224711nonenone523 open30none0none0nonenone121none41 open4251 open0nonenone2none1nonenonenonenone1none1none02nonenone121 open4none0nonenonenonenonenonenonenone
Beijing Fuwai Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing GoBroad Hospital北京高博医院none01 open01 opennonenonenone01 opennonenonenonenonenonenonenonenone02 open04 opennonenone25 opennonenonenonenonenonenone01 open01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Haidian Hospital北京市海淀医院nonenonenonenone02 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Hospital北京医院nonenone151 open4741025nonenonenonenonenone01none2nonenonenone6none2none0none0none1141 opennonenone303 open3none01none8nonenonenonenonenone02none1nonenonenonenonenonenonenone0nonenonenonenonenonenone
Beijing Hospital, Capital Medical University北京市中西医结合医院nonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenone4nonenonenone11nonenonenonenonenonenonenonenonenone
Beijing Huairou Hospital北京怀柔医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing HuiLongGuan Hospital北京回龙观医院nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital北京积水潭医院nonenonenonenonenonenonenonenonenonenone021nonenone16nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4none0nonenonenone0nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital Guizhou Hospital北京积水潭医院贵州医院nonenonenonenonenonenonenonenonenonenone12nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Jishuitan Hospital Liaocheng Hospital北京积水潭医院聊城医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Lu Daopei Hospital北京道培医院nonenonenonenonenonenonenonenonenonenonenone1nonenone1none1none3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Luhe Hospital首都医科大学附属北京潞河医院nonenonenonenonenone7nonenonenone1none002nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenone
Beijing Rehabilitation Hospital首都医科大学附属北京康复医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Sanbo Brain Hospital北京三博脑科医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Shijitan Hospital北京世纪坛医院none191447none28130nonenone1none0nonenonenonenonenone400nonenonenonenonenonenonenonenonenonenonenonenonenone2nonenone1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beijing Stomatological Hospital首都医科大学附属北京口腔医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenone
Beijing Tiantan Hospital首都医科大学附属北京天坛医院nonenonenonenone18nonenone30712 opennonenone140none0nonenonenonenonenone242 opennone1nonenonenone342 opennone1609 opennonenone172 opennonenone61none2none40nonenone1nonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenone
Beijing Tongren Hospital首都医科大学附属北京同仁医院61301534814none821none7none91601 opennone11 open357 opennone0nonenonenone736none3none45242 opennonenone1nonenonenonenonenonenone1none2nonenonenone2nonenone1none0none4nonenonenone
Beijing Tsinghua Changgung Hospital北京清华长庚医院nonenone29nonenone4none121002nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone8nonenone010none1none0nonenonenone10nonenonenonenone1nonenonenonenonenonenonenonenonenone
Beijing United Family Hospital北京和睦家医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenone
Beijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院nonenone67nonenonenonenonenonenonenonenone1nonenonenonenonenonenone26nonenonenonenonenonenonenonenonenone5nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenone70nonenonenonenonenonenonenonenonenone
Beijng Anzhen Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College中国医学科学院肿瘤医院nonenonenonenone9none4nonenonenonenonenonenonenonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Capital Medical University Electric Teaching Hospital北京电力医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Capital Medical University Sanbo Brain Hospital北京三博脑科医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital, Peking Union Medical College首都医科大学附属首都儿童医学中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenone2nonenonenonenone2nonenonenonenone0nonenonenone1nonenonenonenonenonenonenone23nonenonenonenonenonenonenone
China-Japan Friendship Hospital中日友好医院none5none13563 open9nonenonenonenonenone2nonenonenone2nonenone22nonenonenonenonenone60nonenonenonenone262 opennonenone001 opennone190none1100nonenone9nonenonenone10nonenonenonenone0nonenonenonenone
Chinese Medicine Affiliated Shenzhen Hospital北京中医药大学深圳医院(龙岗)nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Chinese Medicine Third Affiliated Hospital北京中医药大学第三附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Chinese PLA General Hospital中国人民解放军总医院8271846 open1406 open176712 open914 open561 open32none1271152 open06 open11 open21 open3730 open011nonenone122 open52 open4461 opennonenone765 open9110023120231601171 open1none02nonenonenonenonenone01nonenonenone
Civil Aviation General Hospital民航总医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongfang Hospital北京中医药大学东方医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone5nonenonenone1none5nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongzhimen Hospital北京中医药大学东直门医院nonenonenonenonenonenonenonenonenonenonenone0none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone7nonenonenonenonenone2none5nonenonenonenonenone14nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Dongzhimen Hospital北京中医药大学东直门医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fangshan Hospital, Beijing University of Chinese Medicine北京市房山区中医医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院none3none1932none218nonenonenone51nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Hospital of Tsinghua University北京华信医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone10nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Integrative Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone340nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone21 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fu Wai Hospital, Peking Union Medical College中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fuwai Hospital中国医学科学院阜外心血管病医院nonenonenonenonenonenonenonenonenonenonenone1none1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone2432 open1503 opennonenone14nonenonenonenonenone21 opennonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
FuWai Hospital, Peking Union Medical Collegenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fuxing Hospital首都医科大学附属复兴医院nonenonenonenonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Guang Anmen Hospital中国中医科学院广安门医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guang'anmen Hospital中国中医科学院广安门医院nonenonenone91 open321 open10122 opennonenonenonenonenone1nonenonenonenonenonenonenone0nonenonenonenonenonenone3nonenonenone20none2nonenonenone1nonenonenonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Medical Sciences Fuwai Hospital中国医学科学院阜外医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院331 open18410 open1033 open1312 open58725 open452 open33335 open101 opennonenonenone8121nonenone3none832 open1nonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking Union Medical College Fuwai Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking Union Medical College Hospital北京协和医院341 open6510 open5421313 open2279 open10610 open521 opennone0none4671 open1272 open1161 open77410 open11711none8477 open69nonenone294 open16892 open327018144431 open212492 opennone51none14221 open321110nonenone0nonenone
Peking University Aerospace Center Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University Cancer Hospital北京大学肿瘤医院2826 open425 open2239 open16122 open342 open11614 opennonenonenonenone4121 open123nonenonenone834 opennonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University First Hospital北京大学第一医院nonenone202 open271 open535 open283 open444 opennone0nonenone41 open261175 opennonenone1366 opennone12nonenone153nonenonenone232 open571 open1114none21811128651 opennone0none01none15none1nonenonenonenone
Peking University International Hospital北大国际医院nonenonenonenonenonenonenonenone1nonenone00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenone3nonenonenonenonenonenonenonenonenonenonenone2none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University People's Hospital北京大学人民医院none2241 open213 open10214 open31 open4422 opennonenone06442 open102 opennone82 open195 open194 open293 open71 open146 opennone01 opennone42 open201 open121 open3nonenonenone1357none1none3nonenonenonenonenonenone51 opennone00none2700nonenonenone0nonenonenonenone
Peking University Shougang Hospital北京大学首钢医院nonenonenonenonenonenonenonenonenonenonenone11none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenone0nonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Peking University Third Hospital北京大学第三医院nonenone121 open262 open514 open162 open282 open232 opennonenone6720070nonenone313 open01none0none22none2nonenone172 open541none102none522 open01 open1none10none1nonenonenone0nonenonenonenonenone0nonenonenonenone
Plastic Surgery Hospital中国医学科学院整形外科医院nonenonenonenonenonenone20nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Plastic Surgery Hospital, Peking Union Medical Collegenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
PUMC Hospital中国医学科学院北京协和医院nonenonenonenonenone0nonenonenonenonenone00none0nonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenonenone
Sanbo Brain Hospital首都医科大学三博脑科医院nonenonenonenonenonenonenone301 opennonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sanbo Brain Hospital, Capital Medical Universitynonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Artillery General Hospital中国人民解放军火箭军特色医学中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shijitan Hospital, Captial Medical University首都医科大学附属北京世纪坛医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Wangjing Hospital中国中医科学院望京医院nonenonenonenonenonenonenonenonenonenonenone2nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xiyuan Hospital中国中医科学院西苑医院nonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone25nonenonenonenonenone0none1nonenonenonenonenonenone9nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Xuanwu Hospital首都医科大学宣武医院2none155262 open61225none071none3nonenone0nonenone71nonenone1none52 open2161 open7nonenone151 open5122 open96nonenonenone7nonenonenone10none2none1nonenonenonenonenonenonenonenonenonenonenonenone
Yuquan Hospital清华大学玉泉医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Beijing.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Beijing on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data